Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
NCT05994339Phase 3Not yet recruiting
- Sponsor
- Laibin People's Hospital
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Laibin People's Hospital. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05994339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05994339.